我們已在上線! 進一步了解
MASS圖示

908 Devices

11.26 USD
-0.63
5.3%
收盤時 已更新 10月16日 下午4:00 EDT
盤前交易
盤後交易
11.26
0.00
0%
1天
-5.3%
5天
-7.86%
1個月
13.51%
3個月
51.96%
6個月
51.75%
今年迄今
121.22%
1年
29.72%
5年
-65.3%
10年
-77.02%
 

關於: 908 Devices Inc develops a suite of purpose-built handheld devices for point-of-need chemical analysis. Leveraging mass spectrometry, optical spectroscopy, analytics and machine learning technologies, the company makes devices that are smaller and more accessible than conventional laboratory instruments. Its devices, including MX908, ThreatID, XplorIR and VipIR, are used to analyze unknown materials and provide actionable answers in health, safety and defense technology applications, addressing the fentanyl and illicit drug crisis, toxic carcinogen exposure and security threats. The company reimagines mass spectrometry technology by developing smaller, lower-cost and simpler-to-operate devices compared to conventional instruments, and generates maximum revenue from the United States.

員工: 172

新聞

正面
中性
負面
市場情緒 3個月
正面 35.7%
中性 50%
負面 14.3%
中性
Business Wire
上個月
908 Devices to Present at the 32nd Annual Gabelli Aerospace & Defense Symposium
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced it will participate in the upcoming 32nd Annual Gabelli Aerospace & Defense Symposium on September 10, 2026, in New York City.908 Devices' management is scheduled to present at 3:45 p.m. Eastern Time. The presentation is webcast and interested parties can register for th.
908 Devices to Present at the 32nd Annual Gabelli Aerospace & Defense Symposium
正面
MarketBeat
上個月
908 Devices Raises 2026 Outlook as Handheld Detection Demand Accelerates
908 Devices NASDAQ: MASS outlined its strategy to expand in handheld chemical detection following second-quarter 2026 results that showed revenue growth, a narrower adjusted EBITDA loss and increasing recurring revenue.
908 Devices Raises 2026 Outlook as Handheld Detection Demand Accelerates
正面
MarketBeat
2 個月前
TG Therapeutics Conference: 908 Devices Bets on Handheld Drug, Chemical Detection
908 Devices outlined its strategy to focus exclusively on handheld chemical and drug detection technologies for public safety and defense markets, following the divestiture of its life-sciences business line about 15 months ago.
TG Therapeutics Conference: 908 Devices Bets on Handheld Drug, Chemical Detection
正面
MarketBeat
2 個月前
908 Devices Eyes Growth in Handheld Drug and Chemical Detection Market
908 Devices NASDAQ: MASS is sharpening its focus on handheld chemical and drug detection systems for public safety, defense and law enforcement following the divestiture of its bioprocessing and biopharma business line, executives said during a Canaccord Genuity discussion.
908 Devices Eyes Growth in Handheld Drug and Chemical Detection Market
正面
Seeking Alpha
2 個月前
908 Devices Q2: Another Solid Report
908 Devices delivered another revenue beat in Q2, as device sales continued to shine. Q2 revenues grew 23% year-over-year to $16.07 million, with product revenue up nearly 35.5% and the installed base expanding 23%. Management raised 2026 revenue guidance to $68–$70 million, implying 21–25% growth, while operating and net losses narrowed.
908 Devices Q2: Another Solid Report
正面
Seeking Alpha
2 個月前
908 Devices: Mission Critical Devices Drive Growth
908 Devices is rated BUY after a 2Q26 earnings beat, strong revenue growth, and a 97% YTD share price gain. MASS benefits from robust demand for chemical detection devices, driven by law enforcement, defense, and volatile geopolitical conditions. Recurring revenue from NIRLab and product upgrades like VipIR underpin stable growth; management raised FY26 revenue guidance to $68–$70M.
908 Devices: Mission Critical Devices Drive Growth
中性
Business Wire
2 個月前
908 Devices to Present at the 17th Annual Midwest IDEAS Investor Conference
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced that CEO and Co-founder Kevin J. Knopp and CFO Joe Griffith will present and host investor meetings at the 17th Annual Midwest IDEAS Conference on Wednesday, August 26, 2026. The Company presentation is scheduled to begin at 9:55 a.m. CT / 10:55 a.m. ET. The presentation is.
908 Devices to Present at the 17th Annual Midwest IDEAS Investor Conference
中性
Seeking Alpha
2 個月前
908 Devices Inc. (MASS) Q2 2026 Earnings Call Transcript
908 Devices Inc. (MASS) Q2 2026 Earnings Call Transcript
908 Devices Inc. (MASS) Q2 2026 Earnings Call Transcript
中性
MarketBeat
2 個月前
908 Devices Q2 Earnings Call Highlights
908 Devices NASDAQ: MASS reported second-quarter revenue growth of 23% as demand from U.S. state and local government customers, FTIR product shipments and its recently acquired NIRLab platform supported results. The company also raised the low end of its full-year revenue outlook while continuing to exclude potential revenue from the U.S. military's AVCAD program from its core guidance.
908 Devices Q2 Earnings Call Highlights
負面
Zacks Investment Research
2 個月前
908 Devices Inc. (MASS) Reports Q2 Loss, Tops Revenue Estimates
908 Devices Inc. (MASS) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.18 per share a year ago.
908 Devices Inc. (MASS) Reports Q2 Loss, Tops Revenue Estimates
價格圖表採用Lightweight Charts™實作